This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Forman, W. B Articles by Shepard, K. Search for Related Content PubMed PubMed Citation Articles by Forman, W. B Articles by Shepard, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer Pain Hazardous Substances DB MORPHINE Social Bookmarking                         What's this?

A novel morphine sulphate preparation: clinical trial of a controlled-release morphine suspension in cancer pain

University of New Mexico School of Medicine and The Albuquerque Veterans Medical Center, Albuquerque, New Mexico

Russell K Portenoy

Pain Service, Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York

Ronald H Yanagihara

South Valley Hospital, Gilroy, California

Curtis Hunt

University of New Mexico Cancer Center, Tumor Registry Department, Albuquerque, New Mexico

Rebecca Kush

Pharmaco Dynamics Research Inc., Austin, Texas

Kirk Shepard

Roxane Laboratories Inc., Columbus, Ohio

In order to determine the efficacy of a novel controlled-release morphine suspension, we performed two prospective sequential open-label studies in patients with pain due to cancer. The studies were identical except for the duration of treatment (three days and 30 days respectively). Sixty-nine patients with a variety of advanced cancers and associated pain participated. Fifty-three patients completed the trials, 38 on the three-day trial and 15 on the 30-day trial. In both groups the amount of morphine required to obtain pain relief was initially established using controlled-release morphine tablets and immediate-release morphine for 'rescue' dosing. Patients were begun on equivalent doses of the study drug in place of the controlled-release tablets. No differences in pain score or the amount of 'rescue' morphine were noted following the switch to the controlled-release morphine suspension. Toxicity was as anticipated for the use of morphine in this situation and no adverse effects were observed during administration of the suspension. These data suggest that this new formulation of morphine is equipotent to conventional controlled-release morphine tablets and provides pain relief for a 12-hour dosing interval. This novel morphine formulation could be especially useful for paediatric patients and for those who have difficulty in swallowing.

Key Words: analgesia • clinical trials • neoplasms • opioids • palliative treatment

Palliative Medicine, Vol. 7, No. 4, 301-306 (1993)
DOI: 10.1177/026921639300700407


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?